Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis - Top-Institutions - MDSpire

Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis

  • By

  • Geert D’Haens

  • Silvio Danese

  • Remo Panaccione

  • David T Rubin

  • Laurent Peyrin-Biroulet

  • Katsuyoshi Matsuoka

  • Edward V Loftus

  • Taku Kobayashi

  • Walid Elsharkawi

  • Rosa Miceli

  • Samia Ahmed

  • Yi Luo

  • Andrew Napoli

  • John Vaile

  • Quentin Dornic

  • Aditya Patel

  • Stefan Schreiber

  • May 13, 2025

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Clinical Trials

  • #2

    Mount Sinai Health System
    Mount Sinai Health System

    New York, NY

    Key Differentiators

    • Gastroenterology
    • Immunology
    • Inflammatory Bowel Disease

  • #3

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Clinical Pharmacology

  • #4

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Clinical Research

  • #5

    Johns Hopkins Medicine
    Johns Hopkins Medicine

    Baltimore, MD

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Immunology

Original Source(s)

Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis

  • by Geert D’Haens, Silvio Danese, Remo Panaccione, David T Rubin, Laurent Peyrin-Biroulet, Katsuyoshi Matsuoka, Edward V Loftus, Taku Kobayashi, Walid Elsharkawi, Rosa Miceli, Samia Ahmed, Yi Luo, Andrew Napoli, John Vaile, Quentin Dornic, Aditya Patel, Stefan Schreiber

  • May 13, 2025

Related Content

The Impact of Metabolic Bariatric Surgery on Inflammatory Bowel Disease Risk and Outcomes in Adults With Obesity: a Propensity-matched, Nationwide, Analysis

Progression of Coronary Calcium Detected on Routine Chest CT Enhances Cardiovascular Risk Assessment in Individuals with Inflammatory Bowel Disease: Findings from a Multicenter Study

Genes Predict Bowel Disease Severity

Large study suggests genetic risk scores could help doctors identify patients who need closer monitoring and earlier treatment

  • March 12, 2026

  • 2 min